HomeCompareMVRBF vs QSR

MVRBF vs QSR: Dividend Comparison 2026

MVRBF yields 243.90% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVRBF wins by $394.59M in total portfolio value
10 years
MVRBF
MVRBF
● Live price
243.90%
Share price
$0.82
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$394.62M
Annual income
$218,439,906.42
Full MVRBF calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — MVRBF vs QSR

📍 MVRBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVRBFQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVRBF + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MVRBF pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVRBF
Annual income on $10K today (after 15% tax)
$20,731.71/yr
After 10yr DRIP, annual income (after tax)
$185,673,920.46/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, MVRBF beats the other by $185,673,590.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVRBF + QSR for your $10,000?

MVRBF: 50%QSR: 50%
100% QSR50/50100% MVRBF
Portfolio after 10yr
$197.32M
Annual income
$109,220,147.15/yr
Blended yield
55.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

MVRBF
No analyst data
Altman Z
1.7
Piotroski
0/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVRBF buys
0
QSR buys
0
No recent congressional trades found for MVRBF or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVRBFQSR
Forward yield243.90%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$394.62M$24.7K
Annual income after 10y$218,439,906.42$387.88
Total dividends collected$375.65M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: MVRBF vs QSR ($10,000, DRIP)

YearMVRBF PortfolioMVRBF Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$35,090$24,390.24$11,038$337.57+$24.1KMVRBF
2$117,533$79,986.88$12,156$345.43+$105.4KMVRBF
3$376,147$250,386.00$13,359$352.69+$362.8KMVRBF
4$1,151,374$748,897.11$14,654$359.36+$1.14MMVRBF
5$3,374,355$2,142,384.97$16,045$365.45+$3.36MMVRBF
6$9,478,533$5,867,972.46$17,539$370.97+$9.46MMVRBF
7$25,546,778$15,404,747.63$19,143$375.96+$25.53MMVRBF
8$66,138,099$38,803,046.68$20,863$380.42+$66.12MMVRBF
9$164,653,072$93,885,306.32$22,708$384.39+$164.63MMVRBF
10$394,618,693$218,439,906.42$24,685$387.88+$394.59MMVRBF

MVRBF vs QSR: Complete Analysis 2026

MVRBFStock

Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.

Full MVRBF Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this MVRBF vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVRBF vs SCHDMVRBF vs JEPIMVRBF vs OMVRBF vs KOMVRBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.